Y-Mabs Therapeutics (YMAB) Income Statement (2018 - 2025)
Income Statement report data from Sep 30, 2018 to Jun 30, 2025 for Y-Mabs Therapeutics (YMAB).
Reported currency: USD
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | ||||||||||||||||||||||||||||
Total Revenue | 20M (-6.60%) | 21M (-21.13%) | 27M (+43.55%) | 18M (-19.04%) | 23M (+14.40%) | 20M (-14.68%) | 23M (+14.23%) | 20M (-1.45%) | 21M (+2.47%) | 20M (-35.61%) | 31M (+150.80%) | 13M (+16.11%) | 11M (+2.96%) | 10M (+9.27%) | 9.60M (+7.02%) | 8.97M (-18.08%) | 11M (+103.53%) | 5.38M | - | - | - | - | - | - | - | - | - | - |
Cost Of Revenue | 2.66M (-11.33%) | 3.00M (-60.73%) | 7.64M (+239.56%) | 2.25M (-25.25%) | 3.01M (+43.33%) | 2.10M (+2.94%) | 2.04M (-21.54%) | 2.60M (-44.09%) | 4.65M (+123.56%) | 2.08M (+2.97%) | 2.02M (-18.55%) | 2.48M (+117.54%) | 1.14M (-37.70%) | 1.83M (+25.34%) | 1.46M (+165.45%) | 550K (+175.00%) | 200K (+122.22%) | 90K | - | - | - | - | - | - | - | - | - | - |
Costof Goods And Services Sold | 2.66M (-11.33%) | 3.00M (-60.73%) | 7.64M (+239.56%) | 2.25M (-25.25%) | 3.01M (+43.33%) | 2.10M (+2.94%) | 2.04M (-21.54%) | 2.60M (-44.09%) | 4.65M (+123.56%) | 2.08M (+2.97%) | 2.02M (-18.55%) | 2.48M (+117.54%) | 1.14M (-37.70%) | 1.83M (+25.34%) | 1.46M (+165.45%) | 550K (+175.00%) | 200K (+122.22%) | 90K | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 17M (-5.81%) | 18M (-5.04%) | 19M (+16.29%) | 16M (-18.05%) | 20M (+10.94%) | 18M (-16.37%) | 21M (+19.37%) | 18M (+10.93%) | 16M (-11.39%) | 18M (-38.26%) | 29M (+192.54%) | 10M (+4.14%) | 9.66M (+11.68%) | 8.65M (+6.27%) | 8.14M (-3.21%) | 8.41M (-21.77%) | 11M (+103.21%) | 5.29M | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | ||||||||||||||||||||||||||||
Research And Development | 11M (-2.29%) | 11M (-6.96%) | 12M (+9.31%) | 11M (-9.48%) | 12M (-7.01%) | 13M (-0.90%) | 13M (-12.83%) | 15M (+27.36%) | 12M (-10.13%) | 13M (-32.19%) | 20M (-11.85%) | 22M (-15.03%) | 26M (+15.32%) | 23M (-20.34%) | 29M (+24.34%) | 23M (+16.94%) | 20M (-8.34%) | 22M (-10.12%) | 24M (+14.28%) | 21M (-30.11%) | 30M (+61.44%) | 19M (+10.64%) | 17M (-14.39%) | 20M (+35.68%) | 14M (+15.83%) | 13M (+13.32%) | 11M (+26.46%) | 8.73M |
Selling General And Administrative | 11M (-13.60%) | 13M (+5.74%) | 12M (-9.04%) | 14M (-21.01%) | 17M (+50.74%) | 11M (+2.60%) | 11M (+9.22%) | 10M (-9.49%) | 11M (-8.00%) | 12M (+13.53%) | 11M (-20.84%) | 14M (-40.94%) | 23M (+71.73%) | 13M (-11.23%) | 15M (+8.22%) | 14M (+3.78%) | 13M (+12.61%) | 12M (-18.18%) | 15M (+25.69%) | 12M (+12.03%) | 10M (+27.80%) | 8.13M (+17.32%) | 6.93M (+47.45%) | 4.70M (+13.53%) | 4.14M (+10.70%) | 3.74M (+23.03%) | 3.04M (+13.43%) | 2.68M |
Operating Expenses | 22M (-8.10%) | 24M (-1.37%) | 25M (+0.04%) | 25M (-16.20%) | 30M (+19.52%) | 25M (+0.90%) | 25M (-4.26%) | 26M (+9.77%) | 23M (-9.12%) | 26M (-16.06%) | 31M (-15.24%) | 36M (-27.26%) | 50M (+36.45%) | 36M (-17.20%) | 44M (+18.27%) | 37M (+10.94%) | 33M (-0.27%) | 34M (-17.85%) | 41M (+25.12%) | 33M (-19.31%) | 40M (+51.21%) | 27M (+12.58%) | 24M (-2.46%) | 24M (+30.76%) | 19M (+14.65%) | 16M (+15.41%) | 14M (+23.29%) | 11M |
Operating Income | ||||||||||||||||||||||||||||
Operating Income | -5.60M (-14.37%) | -6.54M (+10.10%) | -5.94M (-30.69%) | -8.57M (-12.46%) | -9.79M (+41.68%) | -6.91M (+115.94%) | -3.20M (-58.71%) | -7.75M (+7.34%) | -7.22M (-3.73%) | -7.50M (+552.17%) | -1.15M (-95.58%) | -26.02M (-34.85%) | -39.94M (+44.24%) | -27.69M (-22.57%) | -35.76M (+24.60%) | -28.70M (+26.38%) | -22.71M (-19.64%) | -28.26M (+40.67%) | -20.09M (-38.45%) | -32.64M (-19.31%) | -40.45M (+51.21%) | -26.75M (+12.58%) | -23.76M (-2.46%) | -24.36M (+30.76%) | -18.63M (+14.65%) | -16.25M (+15.41%) | -14.08M (+23.40%) | -11.41M |
EBITDA | -5.55M (-14.22%) | -6.47M (+10.98%) | -5.83M (-31.97%) | -8.57M (-11.10%) | -9.64M (+42.81%) | -6.75M (+122.04%) | -3.04M (-59.89%) | -7.58M (+8.29%) | -7.00M (-4.37%) | -7.32M (+695.65%) | -920.00K (-96.43%) | -25.79M (-35.14%) | -39.76M (+44.58%) | -27.50M (-22.47%) | -35.47M (+24.19%) | -28.56M (+25.76%) | -22.71M (-19.27%) | -28.13M (+40.79%) | -19.98M (-38.62%) | -32.55M (-19.33%) | -40.35M (+51.35%) | -26.66M (+12.58%) | -23.68M (-2.59%) | -24.31M (+30.63%) | -18.61M (+14.66%) | -16.23M (+15.43%) | -14.06M (+23.23%) | -11.41M |
Other Income / Expenses | ||||||||||||||||||||||||||||
Interest Income | 2.37M (+75.56%) | 1.35M | -1.61M | 1.92M (+200.00%) | 640K (+45.45%) | 440K (-81.74%) | 2.41M (+1168.42%) | 190K (-82.73%) | 1.10M (-0.90%) | 1.11M | - | -1.51M (+26.89%) | -1.19M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense | - | - | - | - | - | - | - | - | - | - | -760.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Interest Income | 2.37M (+75.56%) | 1.35M | -1.61M | 1.92M (+200.00%) | 640K (+45.45%) | 440K (-81.74%) | 2.41M (+1168.42%) | 190K (-82.73%) | 1.10M (-0.90%) | 1.11M (+46.05%) | 760K | -1.51M (+26.89%) | -1.19M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Other Non Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -370.00K (-67.26%) | -1.13M (+653.33%) | -150.00K (-31.82%) | -220.00K | 62M (+38443.75%) | 160K | -190.00K | 60K (-89.47%) | 570K (-8.06%) | 620K (+40.91%) | 440K (-26.67%) | 600K (+87.50%) | 320K (+1500.00%) | 20K | -10.00K |
Net Income | ||||||||||||||||||||||||||||
Income Before Tax | -3.23M (-37.76%) | -5.19M (-31.17%) | -7.54M (+13.38%) | -6.65M (-27.32%) | -9.15M (+41.42%) | -6.47M (+718.99%) | -790.00K (-89.55%) | -7.56M (+23.53%) | -6.12M (-4.23%) | -6.39M | 1.16M | -27.53M (-33.07%) | -41.13M (+46.53%) | -28.07M (-23.91%) | -36.89M (+27.82%) | -28.86M (+25.81%) | -22.94M | 33M | -19.93M (-39.29%) | -32.83M (-18.72%) | -40.39M (+54.28%) | -26.18M (+13.14%) | -23.14M (-3.26%) | -23.92M (+32.59%) | -18.04M (+13.25%) | -15.93M (+13.30%) | -14.06M (+23.01%) | -11.43M |
Income Tax Expense | 10K (0.00%) | 10K | -750.00K | 350K (+250.00%) | 100K (-37.50%) | 160K (-20.00%) | 200K (+5.26%) | 190K (+5.56%) | 180K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income From Continuing Operations | -3.24M (-37.69%) | -5.20M (-23.42%) | -6.79M (-3.00%) | -7.00M (-24.32%) | -9.25M (+39.52%) | -6.63M (+569.70%) | -990.00K (-87.23%) | -7.75M (+23.02%) | -6.30M (-1.41%) | -6.39M | 1.16M | -27.53M (-33.07%) | -41.13M (+46.53%) | -28.07M (-23.91%) | -36.89M (+27.82%) | -28.86M (+25.81%) | -22.94M | 33M | -19.93M (-39.29%) | -32.83M (-18.72%) | -40.39M (+54.28%) | -26.18M (+13.14%) | -23.14M (-3.26%) | -23.92M (+32.59%) | -18.04M (+13.25%) | -15.93M (+13.30%) | -14.06M (+23.01%) | -11.43M |
Net Income | -3.24M (-37.69%) | -5.20M (-23.42%) | -6.79M (-3.00%) | -7.00M (-24.32%) | -9.25M (+39.52%) | -6.63M (+569.70%) | -990.00K (-87.23%) | -7.75M (+23.02%) | -6.30M (-1.41%) | -6.39M | 1.16M | -27.53M (-33.07%) | -41.13M (+46.53%) | -28.07M (-23.91%) | -36.89M (+27.82%) | -28.86M (+25.81%) | -22.94M | 33M | -19.93M (-39.29%) | -32.83M (-18.72%) | -40.39M (+54.28%) | -26.18M (+13.14%) | -23.14M (-3.26%) | -23.92M (+32.59%) | -18.04M (+13.25%) | -15.93M (+13.30%) | -14.06M (+23.01%) | -11.43M |